Which has better earnings and valuation, ZURA or SLS?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.09 N/A SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A

Is ZURA or SLS more profitable?

SELLAS Life Sciences Group's return on equity of -47.12% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -55.74% -48.07% SELLAS Life Sciences Group N/A -47.12% -42.63%

Which has stronger earnings and valuation, GENB or ZURA?

Generate Biomedicines has higher revenue and earnings than Zura Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Generate Biomedicines $30.30M 52.38 N/A N/A N/A Zura Bio N/A N/A -$99.35M -$1.09 N/A

Is GENB or ZURA more profitable?

Generate Biomedicines' return on equity of 0.00% beat Zura Bio's return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Zura Bio N/A -55.74% -48.07%

Does the media favor GENB or ZURA?

In the previous week, Zura Bio had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 3 mentions for Zura Bio and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.93 beat Zura Bio's score of 0.45 indicating that Generate Biomedicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ZURA or BHVN?

Zura Bio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zura Bio N/A N/A -$99.35M -$1.09 N/A Biohaven N/A N/A -$738.82M -$5.67 N/A

Is ZURA or BHVN more profitable?

Zura Bio's return on equity of -55.74% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -55.74% -48.07% Biohaven N/A -866.46% -137.99%

Does the media refer more to ZURA or BHVN?

In the previous week, Zura Bio had 1 more articles in the media than Biohaven. MarketBeat recorded 3 mentions for Zura Bio and 2 mentions for Biohaven. Zura Bio's average media sentiment score of 0.45 beat Biohaven's score of 0.31 indicating that Zura Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Biohaven 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ZURA or PVLA more profitable?

Zura Bio's return on equity of -55.74% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zura Bio N/A -55.74% -48.07% Palvella Therapeutics N/A -56.87% -42.50%

Does the media prefer ZURA or PVLA?

In the previous week, Zura Bio had 1 more articles in the media than Palvella Therapeutics. MarketBeat recorded 3 mentions for Zura Bio and 2 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 0.94 beat Zura Bio's score of 0.45 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Palvella Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ZURA or GLUE?

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Zura Bio. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 3 mentions for Zura Bio. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Zura Bio's score of 0.45 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Monte Rosa Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zura Bio (ZURA) Competitors

$3.70 +0.12 (+3.35%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.68 -0.02 (-0.49%)

As of 06/12/2026 07:56 PM Eastern

Compare

ZURA vs. SLS, GENB, BHVN, PVLA, and GLUE

Should you buy Zura Bio stock or one of its competitors? MarketBeat compares Zura Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zura Bio include SELLAS Life Sciences Group (SLS), Generate Biomedicines (GENB), Biohaven (BHVN), Palvella Therapeutics (PVLA), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry.

How does Zura Bio compare to SELLAS Life Sciences Group?

Zura Bio (NASDAQ:ZURA) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Zura Bio has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market.

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 12.4% of Zura Bio shares are held by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

SELLAS Life Sciences Group's return on equity of -47.12% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Zura Bio presently has a consensus price target of $10.75, suggesting a potential upside of 190.54%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential upside of 27.71%. Given Zura Bio's stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Zura Bio had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 3 mentions for Zura Bio and 1 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 1.87 beat Zura Bio's score of 0.45 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Zura Bio	Neutral
SELLAS Life Sciences Group	Very Positive

Summary

Zura Bio beats SELLAS Life Sciences Group on 8 of the 14 factors compared between the two stocks.

How does Zura Bio compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and Zura Bio (NASDAQ:ZURA) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

61.1% of Zura Bio shares are held by institutional investors. 12.4% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Generate Biomedicines currently has a consensus price target of $25.40, indicating a potential upside of 105.17%. Zura Bio has a consensus price target of $10.75, indicating a potential upside of 190.54%. Given Zura Bio's higher probable upside, analysts clearly believe Zura Bio is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Generate Biomedicines' return on equity of 0.00% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Zura Bio	N/A	-55.74%	-48.07%

In the previous week, Zura Bio had 1 more articles in the media than Generate Biomedicines. MarketBeat recorded 3 mentions for Zura Bio and 2 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.93 beat Zura Bio's score of 0.45 indicating that Generate Biomedicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Generate Biomedicines has higher revenue and earnings than Zura Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$30.30M	52.38	N/A	N/A	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

Summary

Generate Biomedicines beats Zura Bio on 6 of the 11 factors compared between the two stocks.

How does Zura Bio compare to Biohaven?

Zura Bio (NASDAQ:ZURA) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Zura Bio's return on equity of -55.74% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
Biohaven	N/A	-866.46%	-137.99%

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 12.4% of Zura Bio shares are held by company insiders. Comparatively, 13.8% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Zura Bio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

In the previous week, Zura Bio had 1 more articles in the media than Biohaven. MarketBeat recorded 3 mentions for Zura Bio and 2 mentions for Biohaven. Zura Bio's average media sentiment score of 0.45 beat Biohaven's score of 0.31 indicating that Zura Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biohaven	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zura Bio presently has a consensus price target of $10.75, indicating a potential upside of 190.54%. Biohaven has a consensus price target of $22.27, indicating a potential upside of 96.30%. Given Zura Bio's higher probable upside, equities research analysts clearly believe Zura Bio is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.71

Zura Bio has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

Summary

Zura Bio and Biohaven tied by winning 7 of the 14 factors compared between the two stocks.

How does Zura Bio compare to Palvella Therapeutics?

Zura Bio (NASDAQ:ZURA) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Zura Bio currently has a consensus target price of $10.75, indicating a potential upside of 190.54%. Palvella Therapeutics has a consensus target price of $199.53, indicating a potential upside of 83.38%. Given Zura Bio's higher possible upside, equities research analysts plainly believe Zura Bio is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94

Zura Bio has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.14, suggesting that its stock price is 114% less volatile than the broader market.

Zura Bio's return on equity of -55.74% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
Palvella Therapeutics	N/A	-56.87%	-42.50%

In the previous week, Zura Bio had 1 more articles in the media than Palvella Therapeutics. MarketBeat recorded 3 mentions for Zura Bio and 2 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 0.94 beat Zura Bio's score of 0.45 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palvella Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 12.4% of Zura Bio shares are held by insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Palvella Therapeutics has higher revenue and earnings than Zura Bio. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
Palvella Therapeutics	$42.81M	36.45	-$41.72M	-$4.17	N/A

Summary

Zura Bio and Palvella Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Zura Bio compare to Monte Rosa Therapeutics?

Zura Bio (NASDAQ:ZURA) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Zura Bio presently has a consensus price target of $10.75, suggesting a potential upside of 190.54%. Monte Rosa Therapeutics has a consensus price target of $32.50, suggesting a potential upside of 78.18%. Given Zura Bio's higher possible upside, analysts clearly believe Zura Bio is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

61.1% of Zura Bio shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 12.4% of Zura Bio shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Monte Rosa Therapeutics has higher revenue and earnings than Zura Bio. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A
Monte Rosa Therapeutics	$123.67M	12.46	-$38.63M	-$1.48	N/A

Zura Bio has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat Zura Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-55.74%	-48.07%
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Zura Bio. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 3 mentions for Zura Bio. Monte Rosa Therapeutics' average media sentiment score of 1.21 beat Zura Bio's score of 0.45 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monte Rosa Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zura Bio has a beta of 0.03, indicating that its share price is 97% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

Summary

Monte Rosa Therapeutics beats Zura Bio on 9 of the 15 factors compared between the two stocks.

Get Zura Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZURA vs. The Competition

Export

Metric	Zura Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$351.06M	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-3.39	19.82	24.21	24.42
Price / Sales	N/A	305.72	512.05	109.98
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	2.68	8.32	10.66	6.83
Net Income	-$99.35M	$23.94M	$3.57B	$337.67M
7 Day Performance	8.82%	3.53%	0.84%	2.68%
1 Month Performance	-23.40%	-2.55%	-0.34%	1.56%
1 Year Performance	208.33%	44.82%	25.40%	30.59%

Zura Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZURA Zura Bio	2.7468 of 5 stars	$3.70 +3.4%	$10.75 +190.5%	+208.3%	$351.06M	N/A	N/A	3	News Coverage
SLS SELLAS Life Sciences Group	1.8741 of 5 stars	$8.33 -8.2%	$10.00 +20.0%	+371.7%	$1.55B	N/A	N/A	10	Positive News
GENB Generate Biomedicines	N/A	$11.97 -7.7%	$25.40 +112.2%	N/A	$1.53B	$30.30M	N/A	312	News Coverage High Trading Volume
BHVN Biohaven	2.6238 of 5 stars	$10.13 -11.4%	$22.27 +119.9%	-26.5%	$1.52B	N/A	N/A	239
PVLA Palvella Therapeutics	2.4947 of 5 stars	$104.67 -7.0%	$199.53 +90.6%	+334.4%	$1.50B	$42.81M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZURA) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zura Bio (ZURA) Competitors

ZURA vs. SLS, GENB, BHVN, PVLA, and GLUE

How does Zura Bio compare to SELLAS Life Sciences Group?

Summary

How does Zura Bio compare to Generate Biomedicines?

Summary

How does Zura Bio compare to Biohaven?

Summary

How does Zura Bio compare to Palvella Therapeutics?

Summary

How does Zura Bio compare to Monte Rosa Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA vs. The Competition

Zura Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zura Bio (ZURA) Competitors

ZURA vs. SLS, GENB, BHVN, PVLA, and GLUE

How does Zura Bio compare to SELLAS Life Sciences Group?

Which has more risk and volatility, ZURA or SLS?

Do insiders and institutionals hold more shares of ZURA or SLS?

Is ZURA or SLS more profitable?

Which has better earnings and valuation, ZURA or SLS?

Do analysts prefer ZURA or SLS?

Does the media prefer ZURA or SLS?

Summary

How does Zura Bio compare to Generate Biomedicines?

Do institutionals and insiders have more ownership in GENB or ZURA?

Do analysts recommend GENB or ZURA?

Is GENB or ZURA more profitable?

Does the media favor GENB or ZURA?

Which has stronger earnings and valuation, GENB or ZURA?

Summary

How does Zura Bio compare to Biohaven?

Is ZURA or BHVN more profitable?

Do insiders and institutionals have more ownership in ZURA or BHVN?

Which has stronger valuation & earnings, ZURA or BHVN?

Does the media refer more to ZURA or BHVN?

Do analysts recommend ZURA or BHVN?

Which has more volatility and risk, ZURA or BHVN?

Summary

How does Zura Bio compare to Palvella Therapeutics?

Do analysts recommend ZURA or PVLA?

Which has more volatility & risk, ZURA or PVLA?

Is ZURA or PVLA more profitable?

Does the media prefer ZURA or PVLA?

Do insiders & institutionals have more ownership in ZURA or PVLA?

Which has better earnings and valuation, ZURA or PVLA?

Summary

How does Zura Bio compare to Monte Rosa Therapeutics?

Do analysts prefer ZURA or GLUE?

Do institutionals & insiders hold more shares of ZURA or GLUE?

Which has stronger valuation & earnings, ZURA or GLUE?

Is ZURA or GLUE more profitable?

Does the media refer more to ZURA or GLUE?

Which has more volatility and risk, ZURA or GLUE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZURA vs. The Competition

Zura Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools